

Docket No. T2315-908010US02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Raymond J. Bergeron, Jr. :
Serial No.: 10/673,227 : Art Unit:
Filed: September 30, 2003 :
For: Method and Composition for Treatment of : Examiner:
Irritable Bowel Disease

INFORMATION DISCLOSURE STATEMENT

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with Applicants duty of disclosure, the following information is submitted for consideration by the U.S. Patent and Trademark Office in connection with the above-identified application.

Since this statement is filed prior three (3) months of the filing date of this application, and prior to the mailing of the first office action, no fee is believed to be required.

The application relies, under 35 USC §120, on the earlier filing date of prior U.S. Application 10/209,638, which is a Divisional Application of Application Serial No. 09/987,694 filed November 15, 2001. The references identified on the attached Form PTO-1449 were submitted to and/or cited by the applicant or the Patent Office in the prior application and, therefore copies are not required to be provided. (see 37 CFR §1.98(d)).

It is respectfully requested that the Examiner fully consider each of the documents, initial the enclosed Form PTO-1449 in the appropriate place to indicate that the document has been considered, and return a copy of the initialed form to the undersigned in accordance with MPEP Section 609.

Respectfully submitted,

MILES & STOCKBRIDGE


A handwritten signature in black ink, appearing to read 'Dennis P. Clarke', with a stylized, flowing script.

Dennis P. Clarke
Registration No. 22,549

Filed: February 25, 2004

Customer No. 000181

1751 Pinnacle Drive
Suite 500
McLean, Virginia 22102-3833
Telephone: (703) 903-9000
Facsimile: (703) 610-8686




PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. T2315-908010US02	SERIAL NUMBER 10/673,227
	APPLICANT Raymond J. Bergeron, Jr.	
	FILING DATE September 30, 2003	GROUP ART UNIT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	4,239,768	12/16/1980	Rasmussen			
	4,562,188	12/31/1985	Kuhla, et al.			
	4,701,457	10/20/1987	Yelnosky, et al.			
	4,745,131	05/17/1988	Yelnosky, et al.			
	4,843,074	06/27/1989	Rzeszotarski, et al.			
	4,877,779	10/31/1989	Rzeszotarski, et al.			
	4,970,207	11/13/1990	Sato, et al.			
	5,043,447	08/27/1991	Pascal, et al.			
	5,342,945	08/30/1994	Bergeron			
	5,393,757	02/28/1995	Bergeron, Jr., et al.			
	5,455,277	10/03/1995	Bergeron			
	5,462,970	10/31/1995	Bergeron, Jr., et al.			
	5,472,943	12/05/1995	Crain, et al.			
	5,510,390	04/23/1996	Bergeron, Jr.			
	5,512,578	04/30/1996	Crain, et al.			
	5,580,876	12/03/1996	Crain, et al.			
	5,585,348	12/17/1996	Crain, et al.			
	5,677,352	10/14/1997	Bergeron, Jr., et al.			
	5,767,125	06/16/1998	Crain, et al.			
	5,827,894	10/27/1998	Bergeron			
	5,866,613	02/02/1999	Bergeron			
	5,962,533	10/05/1999	Bergeron, Jr.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	




PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. T2315-908010US02	SERIAL NUMBER 10/209,638
	APPLICANT Raymond J. Bergeron, Jr.	
	FILING DATE September 30, 2003	GROUP ART UNIT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	6,034,139	03/07/2000	Bergeron			
	6,147,262	11/14/2000	Bergeron			
	6,184,232	02/06/2001	Bergeron, Jr.			
	6,235,794	05/22/2001	Bergeron, Jr.			
	6,262,125	07/17/2001	Bergeron, Jr.			
	6,274,630	08/14/2001	Bergeron, Jr.			
	6,297,287	10/02/2001	Bergeron, Jr.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	



PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. T2315-908010US02	SERIAL NUMBER 10/209,638
	APPLICANT Raymond J. Bergeron, Jr.	
	FILING DATE September 30, 2003	GROUP ART UNIT

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	American Gastroenterological Association (AGA) Medical Position Statement: Irritable Bowel Syndrome. Gastroenterology 112:2118-2119 (1997)
	Drossman D.A., Whitehead W.E., Camilleri M., "Irritable bowel syndrome: a technical review for practice guideline development", Gastroenterology 112:2120-2137 (1997)
	Snape W.J. Jr., "Irritable bowel syndrome", In: Bockus Gastroenterology, 5 th edition W.S. Haubrich, F. Schoffner, ed.) Philadelphia: W.B. Saunders, pp. 1619-1636 (1995)
	Dalton, C. and Drossman, D.A., Am. Fam. Physician 1997 55(3):875-880
	Camilleri, M. and Choi, M.-G., Aliment Pharmacol Ther 1997 11(1):3-15)
	Drossman, D.A. et al., Gastroenterology 1988 95:701-708; Gaynes BN, Drossman D.A.: The role of psychosocial factors in irritable bowel syndrome. Baillieres Best Prac Res Clin Gastroenterol 13:437-452, 1999
	Jones J., Boorman J., Cann P., Forbes A., Gomborone J., Heaton K., Hungin P., Libby G., Spiller R., Read N., Silk D., Whorrell P.: British society of gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 47:ii 1 -ii 19, 2000
	Drossman, D.A., Dig Dis Sci 1993 38:1569-1580
	Talley, N.J. et al., Gastroenterology 1995 109:1736-1741
	K.B. Klein, Controlled treatment trials in the irritable bowel syndrome: a critique, Gastroenterology 95:232-241, 1988
	Dietary fiber, food intolerance, and irritable bowel syndrome, Nutrition Reviews 48: 343-346, 1990
	W.L. Hasler and C. Owyang, Irritable bowel syndrome, In: Textbook of Gastroenterology, Ed. by T. Yamada, J.B. Lippincott Company, Philadelphia, Pa., 1696-1714 (1991)
	M.M. Schuster, Irritable bowel syndrome, In: Gastrointestinal Disease, Pathophysiology Diagnosis and Management, Fourth Edition, Ed. by M.H. Sleisenger, J.S. Fordtran, W.B. Saunders Company, Philadelphia, Pa., 1402-1418 (1989)
	W.S. Haubrich Irritable bowel Syndrome, Gastroenterology, Fourth Edition, Ed. by J.E. Berk, W.B. Saunders Company, Philadelphia, Pa., 2425-2444 (1985)
	Jones J., Boorman J., Cann P., Forbes A., Gomborone J., Heaton K., Hungin P., Kumar D., Libby G., Spiller R., Read N., Silk D., Whorwell P: British society of gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 47:ii 1 -ii 19, (2000)
	Committee, Gastroenterology 1997 112:2120-2137; Pace, F. et al., Digestion 1995 56:433-442
	Chami, T.N. et al., Am J Gastroenterol 1993 88:1568 [abstract]
	Joshi et al., Anesthesiol. 1999, 90(4): 1007-11
	Konieczko, K.M. et al., Br J Anaesth 1988 61(3):313-23
	Dapoigny, M. et al., Dig Dis Sci 1995 40(10):2244-9
	Gue M., et al., Gastroenterology 1994 107(5):1327-34

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	



PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. T2315-908010US02	SERIAL NUMBER 10/209,638
	APPLICANT Raymond J. Bergeron, Jr.	
	FILING DATE September 30, 2003	GROUP ART UNIT

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Wang, L. and Gintzler, A.R., Jneurochem 1995 64(3):1102-6
	Crain, S.M. and Shen, K.-F., Proc Natl Acad Sci USA 1995 92:10540-10544
	Crain, S.M., and Shen, K.-F., Trends Pharmacol Sci 1998 19:358-365
	Ann N Y Acad Sci 1998 845:106-25
	Shen, K.-F. and Crain, S.M., Brain Res 1997 757(2):176-90
	Joshi et al., Anesthesiol. 1999, 90(4): 1007-11
	Gan, T.J. et al., Anesthesiol. 1997 87:1075-1081
	Slepy V.D., Stella M., Pezzotto S.M., Kraier L., Burde L., Wohlwend K., Razzari E., Polento L.; Irritable bowel syndrome clinical and psychopathological correlations; Dig Dis Sci 44:1008-1012, 1999
	Schmulson M.W., Chang L.: Diagnostic approach to the patient with irritable syndrome; Am J Med 107:20S-26S, 1999
	Gaynes B.N., Drossman D.A.: The role of psychosocial factors in irritable bowel syndrome; Baillieres Best Prac Res Clin Gastroenterol 13:437-452, 1999
	Jones J., Boorman J., Cann P., Forbes A., Gomborone J., Heaton K., Hungin P., Kumar D., Libby G., Spiller R., Read N., Silk D., Whorwell P.: British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome; Gut 47:ii 1 -ii 19, 2000
	Collins S.M., Vallance B., Barbara G., Borgaonkar M.: Putative inflammatory and immunological mechanisms in functional bowel disorders; Baillieres Best Prac Res Clin Gastroenterol 13:429-436, 1999
	Farthing M.J.; Irritable bowel syndrome: New pharmaceutical approaches to treatment; Baillieres Best Prac Res Clin Gastroenterol 13:461-471, 1999
	Tansy M.F., Martin J.S., Landin W.E., Kendall F.M., Melamed S.: Spermine and spermidine as inhibitors of gastrointestinal motor activity; Surg Gyn Obst 154:74-80, 1982
	Melamed S., Carlson G.R., Moss J.N., Belair E.J., Tansy M.R.; GI pharmacology of polyethyleneimine I: Effects on gastric emptying in rats; J Pharm Sci 66:899-901, 1977
	Tansy M.F., Martin J.S., Innes D.L., Kendall F.M., Mellamed S., Moss J.N.; GI pharmacology of polyethyleneimine II: Motor activity in anesthetized dogs; J Pharm Sci 66:902-904, 1977
	Belair E.J., Carlson G.R., Melamed S., Moss J.N., Tansy M.R.; Effects of spermine and spermidine on gastric emptying in rats; J Pharm Sci 70:347, 1981
	Bergeron, R.J., Yao G.W., Yao H., Weimar W.R., Sninsky C.A., Raisler R., Feng Y., Wu Q., Gao F.; "Metabolically programmed polyamine analogue antidiarrheals; J. Med Chem 39:2461-2471, 1996
	Tato T.L., Sninsky C.A., Bergeron R.J.; Structural specificity of synthetic analogues of polyamines and their effect on gastrointestinal motility. In Polyamines and the gastrointestinal tract, Falk Symposium, no 62. R.H Dowling, U.R. Folsch, C. Loser (eds), Boston, Kluwer Academic, 1991
	Sninsky C.A., Bergeron R.; Potent anti-diarrheal activity of a new class of compounds: Synthetic analogs of the polyamine pathway. Gastroenterology 104:A54, 1993
	Bergeron R.J., Weimar W.R., Luchetta G., Sninsky C.A., Wiegand J.; Metabolism and pharmacokinetics of N ¹ ,N ¹⁴ -diethylhomospermine. Drug Metab Dispos 24:334-343, 1996
	Bergeron R.J., Wiegand J., Weimar W.R., Snyder P.S., Porter C.W., Braylan R.C.; Chemical resection of the exocrine pancreas; Pancreas, 2001 -Submitted

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	



PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. T2315-908010US02	SERIAL NUMBER 10/209,638
	APPLICANT Raymond J. Bergeron, Jr.	
	FILING DATE September 30, 2003	GROUP ART UNIT

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Bergeron R.J., Weimar W.R., Luchetta G., Streiff R.R., Wiegand J., Perrin J., Schreier K.M., Porter C., Dimova H.; "Metabolism and pharmacokinetics of N ¹ ,N ¹¹ -diethylhomospermine", <i>Drug Metab Dispos</i> 23:117-1125, 1995
Bergeron R.J., Wiegand J., McManis J.S., Weimar W.R., Smith R.E., Algee S.E., Fannin T.L., Slusher M.A., Snyder P.S.; "Polyamine analogue antidiarrheals: A structure-activity study", <i>J Med Chem</i> 44:232-244, 2001
Bergeron R.J., McManis J.S., Liu C.Z., Feng Y., Weimar W.R., Luchetta G.R., Wu Q., Ortiz-Ocasio J., Vinson J.R.T., Kramer D., Porter C.; "Antiproliferative properties of polyamine analogues: A structure-activity study", <i>J Med Chem</i> 37:3464-3476, 1994
Bergeron R.J., Feng Y., Weimar W.R., McManis J.S., Dimova H., Porter C., Raisler B., Phanstiel O.; "A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics", <i>J Med Chem</i> 40:1475-1494, 1997
Bergeron R.J., McManis J.S., Weimar W.R., Schreier K.M., Gao F., Wu Q., Ortiz-Ocasio J., Luchetta G.R., Porter C., Vinson J.R.T.; "The role of charge in polyamine analogue recognition", <i>J Med Chem</i> 38:2278-2285, 1995
Bergeron et al., <i>J Med Chem</i> 44:232-244 (2001)
Almy T.P., Tulin M.; "Alterations in colonic function in man under stress: Experimental production of changes simulating the "irritable colon". <i>Gastroenterology</i> 8:616-626, 1947
Drossman D.A., Powell D.W., Sessions J.T.; "The irritable bowel syndrome", <i>Gastroenterology</i> 73:811-822, 1977
Narducci F., Snape W.J., Battle W.M., London R.L., Cohen S.; "Increased colonic motility during exposure to a stressful situation". <i>Dig Dis Sci</i> 30:40-44, 1985
Tache Y., Monnikes H., Bonaz B., Rivier J.; "Role of CRF in stress-related alterations and colonic motor function", <i>Ann N Y Acad Sci</i> 697:233-243, 1993
Kishibayashi N., Miwa Y., Hayashi H., Ishi A., Ichikawa S., Nonaka H., Yokoyama T., Suzuki F.; "5-HT ₃ receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome", <i>J Med Chem</i> 36:3286-3292, 1993
Lenz H.J., Raedler A.S., Greten H., Vale W.W., Rivier J.E.; "Stress-induced gastrointestinal secretory and motor responses in rats are mediated by endogenous corticotropin-releasing factor", <i>Gastroenterology</i> 95:1510-1517, 1988
Williams C.L., Villar R.G., Peterson J.M., Burks T.F.; "Stress-induced changes in intestinal transit in the rat: A model for irritable bowel syndrome", <i>Gastroenterology</i> 94:611-621, 1988
Barone F.C., Deegan J.F., Price W.J., Fowler P.J., Fondacaro J.D., Ormsbee H.S.I.; "A model of stress-induced increased fecal output and colonic transit", <i>Gastroenterology</i> 90:A1337, 1986
Barone F.C., Deegan W.J., Fowler P.J., Fondacaro J.D., Ormsbee H.S.I.; "Stress-induced diarrhea is not associated with abnormal gut secretion", <i>Gastroenterology</i> 90:A1337, 1986
Barone F.C., Deegan J.F., Price W.J., Fowler P.J., Fondacaro J.D., Ormsbee H.S.I.; "Cold-resistant stress increases rat fecal pellet output and colonic transit", <i>Am J Physiol</i> 258:G329-G337, 1990
Gue M., Junien J.L., Bueno L.; "Conditioned emotional response in rats enhances colonic motility through the release of corticotropin-releasing factor", <i>Gastroenterology</i> 100:964-970, 1991
Bonaz B., Tache Y.; "Water-avoidance stress-induced c-fos express in the rat brain and stimulation of fecal output: Role of a corticotropin-releasing factor", <i>Brain Res</i> 641:21-28, 1994
Enck P., Merlin V., Erckenbrecht J.F., Weinbeck M.; "Stress effects on gastrointestinal transit in the rat", <i>Gut</i> 30:455-459, 1989
Mormikes H., Schmidt B.G., Tache Y.; "Psychological stress-induced colonic transit in rats involves hypothalamic corticotropin-releasing factor", <i>Gastroenterology</i> 104:716-723, 1993
Sninsky C.A., Broome T.A., Brooderson R.J., Bergeron R.J.; "Diethylhomospermine, a synthetic polyamine analog, prevents psychological stress-induced acceleration of colonic transit in rats", <i>Gastroenterology</i> 106:A569, 1994
*Shiho Okano, et al. "Effects of TAK-637, a Novel Neurokinin-1 Receptor Antagonist, on Colonic Function in Vivo", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 298, No. 2, pp 559-564, 2001
*Seiji Kobayashi, et al., "Effects of YM905, a Novel Muscarinic M ₃ -Receptor Antagonist, on Experimental Models of Bowel Dysfunction in Vivo", <i>Jpn. J. Pharmacol.</i> 86, 281-288 (2001)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	